In 1907, the US-American pathologist George Hoyt Whipple (Biography) reported “a hitherto undescribed disease characterized anatomically by deposits of fat and fatty acids
in the intestinal and mesenteric lymphatic tissues”. ( 1 ) He interpreted his autopsy findings as intestinal lipodystrophy. In 1949, a newly developed histochemical stain was first
applied to tissue from a patient with the disease. The positive reaction with Periodic Acid Schiff´s reagent (PAS) revealed that the foamy macrophages, which were described previously by Whipple, did in fact contain a
glycoprotein material but not lipids. ( 2 ) In 1960/1961, when electron microscopy entered into medicine, the PAS positive material in the cytoplasm of macrophages was identified as rod-shaped bacteria. ( 3, 4 , 5 )
Since, Whipple´s disease is considered to be an infective disorder which can be treated successfully with antibiotics. In 1963 and 1970, autopsy findings (in untreated patients) and clinical observations (in
untreated or treated patients) illustrated that infection with the gram-positive Whipple´s disease bacterium is frequently not limited to the small intestine and its lymph nodes, and may also affect any other organs. (
6, 7 ) Thus, Whipple´s disease is a systemic disorder. In 1991 and 1992, with the advent of molecular methods, the still uncultured bacterium of Whipple´s disease was eventually characterized as a peculiar
species within the bacterial family of actinomycetes. ( 8, 9 ) A new name was proposed, Tropheryma whippelii. ( 9 ) This name is widely used. in 2000, the first successful in-vitro cultivation was done supported by human fibroblasts. (10)
In 2003, the complete bacterial genome is sequenced and analyzed. ( 11, 12 ) |